BETHESDA, Md., Oct. 14 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) today announced that the company will be presenting at the Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:00 p.m. EDT on October 21, 2010, at the New York Academy of Medicine in New York.
Dr. Marnix Bosch, Chief Technical Officer, will provide an overview of the Company's DCVax® technology and unprecedented long-term clinical trial results.
There will be a corresponding live webcast of the conference, which can be accessed by visiting http://www.mdbpartners.com/vaccine.
Hosted by MD Becker Partners and BioBusiness.TV, the Cancer Immunotherapy: A Long-Awaited Reality conference includes keynote speakers, panelist and plenary sessions, company presentations, and intimate networking opportunities to meet the needs of all attendees. Pre-registration is required and attendance is limited to 150 individuals. To register, or to obtain more information, please visit http://www.mdbpartners.com/vaccine or contact MD Becker Partners directly at email@example.com.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company's lead clinical trial is a 240-patient Phase II trial in GBM. The Company also previously received clearance from the FDA for a 600+ patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the pre-clinical development stage.
For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
About MD Becker Partners
MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. The firm also works with venture capitalists, institutional investors, and others that provide capital to these companies. As a strategic advisor and partner, MD Becker Partners provides a full range of services to help its clients increase visibility, unlock stakeholder value, and access resources to grow their business. To accomplish this, the firm integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. For more information visit http://www.mdbpartners.com.
BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives. The company creates video-based, industry focused business news and analysis programs. BioBusiness.TV produces and syndicates videos ranging from news and stock picks, to equity analyst insights, as well as C-level executive interviews on strategy, management, policy, marketing, science, and more. BioBusiness.TV's latest Original Series, "The Stem Cell Review," is a 10-part TV program on the science, medical applications, and business of stem cells, which provides a clear and concise understanding of the state of stem cells today, with the additional depth and expertise you would come to expect from the most renowned authorities in the field. For more information, visit http://www.biobusiness.tv.
|SOURCE Northwest Biotherapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved